A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

201160 citationsJournal Article

Authors

Good health and well-being

Published in: Investigational New Drugs

Volume 30, Issue 4, pp. 1597-1606

Field-Weighted Citation Impact: 3.52